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Methods: To analyze the long-term outcome of dynamic ardiomyoplasty, we 
retrospectively studied 127 consecutive patients who underwent this proce- 
dure in Paris, France (n = 76), Sho Paulo, Brazil (n = 37), and Portland, 
Oregon (n = 14). Preoperative data were collected for patients operated on 
between January 1985 and June 1994 and examined with respect to effect on 
long-term survival. Patients had a mean age of 50 - 13 years and were 
predominantly male (82%). In 46% the cause of disease was ischemic. 
Concomitant operations were performed in 22 patients. Results: Operative 
mortality was 12% (15/127). Kaplan-Meier survival - standard error at 1 
through 5years was 73% -+ 4%, 57% _ 5%, 49% _ 6%, 44% -+ 6%, and 40% 
-+ 7%, respectively. There was a distinct improvement at 6 months in New 
York Heart Association functional class (3.2 +- 0.05 vs 1.7 -+ 0.07, p < 
0.0001) and a small but significant increase in left ventricular ejection 
fraction (20% --. 0.8% vs 23% _ 1.5%, p = 0.04). Ninety-day mortality was 
associated with low right ventricular ejection fraction, a blunted hemody- 
namic response to exercise testing, and requirement for an intraaortic 
balloon pump at the time of the operation. Using a stepwise Cox regression 
method of multivariable survival analysis (n = 101), we determined that 
atrial fibrillation, New York Heart Association class IV, high pulmonary 
capillary wedge pressure, and balloon pump use were independent vari- 
ables simultaneously associated with poor overall survival. When metabolic 
testing variables were added to this model, peak oxygen consumption 
eliminated both pulmonary capillary wedge pressure and functional class 
from the model, albeit with fewer (n = 74) patients. Conclusion: Dynamic 
cardiomyoplasty is an evolving therapy for symptomatic congestive heart 
failure, the results of which may be enhanced by intelligent, risk-sensitive 
patient selection. (J Thorac Cardiovasc Surg 1996;112:1640-50) 
D Ynamic cardiomyoplasty was first performed clinically in 1985.1 It has since been used in the 
treatment of adult congestive h art failure in an 
estimated 600 patients worldwide. After the pio- 
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neering efforts of the Broussais Hospital group in 
Paris, the clinical application of dynamic cardio- 
myoplasty has expanded rapidly throughout Europe, 
South America, Canada, and the United States. 
Outcomes analyses published to date have shown 
improvement in left ventricular ejection fraction, z-4 
increases in stroke volume 4and stroke work index, 3 
dramatic improvements in New York Heart Associ- 
ation (NYHA) functional class, 2-5 and improvement 
in cardiopulmonary oxygen use on exercise testing. 5
A few reports to date 6' 7 have examined the factors 
associated with operative mortality. However, only 
one study 8has attempted to identify the preopera- 
tive factors that adversely affect long-term survival 
after dynamic ardiomyoplasty. 
The purpose of this report was to produce a Cox 
hazard model that would identify which patients had 
a better chance of long-term survival after dynamic 
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cardiomyoplasty. This was done by combining the 
long-term results of dynamic ardiomyoplasty from 
three major centers: The H6pital Broussais, Paris, 
France; The Instituto do Curacao, Silo Paulo, Bra- 
zil; and St. Vincent Hospital, Portland, Oregon. 
Patients and methods 
Patient selection criteria. Patients elected for cardio- 
myoplasty were at high risk of dying within 1 year of 
severe cardiomyopathy. These included patients with 
NYHA class III or IV congestive heart failure (CHF) that 
was refractory to (i.e., did not improve despite) pharma- 
cologic therapy, a left ventricular ejection fraction less 
than 40%, left ventricular end-diastolic pressure or pul- 
monary capillary wedge pressure greater than 15 mm Hg, 
and an age between 18 and 80 years. Selected patients 
must be in stable enough condition to withstand the 
12-week conditioning period required to transform the 
type II skeletal muscle fibers of the latissimus dorsi to type 
I, fatigue-resistant fibers capable of contracting up to 60 
times per minute. 9 As such, patients with arrhythmias 
necessitating an implantable device, vital capacity less 
than 55% of predicted, preoperative dependence on in- 
travenous inotropic agents, life-threatening oncardiac 
disease, or those with previous cardiac operations were 
excluded. 
The details of the surgical procedure have been well 
described 5,lo and will not be repeated here. Patients were 
evaluated before the operation and every 6 months by 
heart catheterization, radionuclide ventriculography, 
echocardiogram, and, when available, by cardiopulmonary 
exercise testing using a metabolic stress exercise protocol. 
Preoperative data were then examined with respect o 
their effect on short-term and long-term survival. 
Statistical analysis. Data were collected separately at 
each of the three individual centers during the entire study 
period. In September 1994, on mutual agreement, these 
data were combined and collated to produce the analyses 
presented herein. Statistical Package for Social Sciences 
(SPSS) software (SPSS, Inc., Chicago, Ill.) was used to 
analyze all data. Results are reported as mean +- standard 
error of the mean. Univariate comparisons were per- 
formed with two-tailed t tests for continuous variables and 
Pearson's )~ statistic for categorical variables. Significance 
levels were set at p < 0.05. The Kaplan-Meier product- 
limit method 11 was used to describe survival after cardio- 
myoplasty. A forward, variable selection, Cox propor- 
tional hazard model 12 was used to evaluate the effect of 
risk factors on survival. To assess the fit of the resultant 
model, we plotted the logarithm of each patient's calcu- 
lated hazard multiplier against his or her own actual 
survival to date. 
Results 
Patient population. Between January 1985 and 
June 1994, 127 patients meeting the selection crite- 
ria underwent dynamic ardiomyoplasty at The H6- 
pital Broussais, Paris, France (n = 76), Instituto de 
Curacao, Silo Paulo, Brazil (n = 37), and Provi- 
dence St. Vincent Hospital and Medical Center, 
Portland, Oregon (n = 14). Mean age was 50 -+ 13 
years and 82% of the population was male. Approx- 
imately half (58/127) had ischemic ardiomyopathy; 
in the remainder the etiology was classified as 
idiopathic. The mean NYHA class was 3.26 _+ 0.05 
(NYHA class IV, 33 patients; III, 89 patients; II, 2 
patients; missing, 4 patients). A single patient un- 
derwent cardiomyoplasty with the right latissimus 
dorsi muscle, and 126 patients underwent left latis- 
simus cardiomyoplasty in either the anterior or 
posterior positions, a° A concomitant cardiac proce- 
dure was performed on 22 patients: left ventricular 
aneurysm resection, 2 patients; coronary bypass 
procedure, 7 patients; mitral valve repair, 6 patients; 
left ventricular aneurysm repair plus coronary by- 
pass, 2 patients; coronary bypass plus mitral valve 
repair, 1 patient; left ventricular aneurysm plus 
mitral valve repair, 1 patient; right ventricular tumor 
resection plus coronary bypass plus valve repair, 1 
patient; and Fontan inferior vena cava-pulmonary 
artery valved conduit, 1 patient. Complete preoper- 
ative demographic, ardiac, exercise, and surgical 
data are presented in Table I. 
Thirty-day operative mortality was 12% (15/127). 
Procedural mortality, defined as any death occurring 
up to 90 days after the operation, was 18% (20/113). 
Ninety days is believed to be a more clinically 
relevant cutoff for perioperative cardiomyoplasty 
mortality because it spans the 12-week skeletal 
muscle conditioning period required to achieve op- 
timal cardiac augmentation. 
A comparison of procedural survivors versus 90- 
day mortality is presented in Table II. Univariate 
analyses of patient-related variables revealed several 
potential factors associated with 90-day mortality. 
Significant differences are seen in both systolic and 
diastolic blood pressures at rest and during exercise. 
In addition, the increase in systolic blood pressure in 
response to exercise was significantly better in the 
procedural survivors, as was the peak oxygen con- 
sumption. The only surgical factor that was found to 
be associated with procedural mortality was the 
requirement for an intraaortic balloon pump 
(IABP) at the time of the operation. Poor right 
ventricular ejection fraction was also significantly 
associated with procedural mortality. 
Procedural survivors had a significant increase in 
postoperative l ft ventricular ejection fraction at 6 
months as compared with preoperative values (20 +_ 
2 vs 23 _+ 2, p = 0.04). This improvement was 
sustained through 12 months (Fig. 1). The clinical 
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Table I. Patient population: descriptive statistics 
Variable Mean ± SD Percentage n 
Demographics 
Age (yr) 50 ± 13 127 
Male sex 82 127 
Ischemic ause 48 127 
NYHA class 3.3 _+ 0.5 123 
Cardiac parameters 
Atrial fibrillation 33 127 
Cardiac index (L/min/m 2) 2.3 + 0.6 104 
Cardiothoracic ratio (CXR) 0.56 _+ 0.07 120 
End-diastolic diameter (mm) 71 _+ 10 72 
EDVI (ml/m 2) 153 _+ 82 15 
LVEDP (ram Hg) 23 + 10 102 
LVEF (%) 20 ± 10 119 
LVSWI (gm/m 2per beat) 24 _+ 12 93 
PAP mean (mm Hg) 31 ± 14 109 
PCWP (ram Hg) 22 ± 10 106 
PVCs per hour 38 2 143 91 
PVR (dynes) 227 _+ 180 99 
RVEF (%) 26 ± 10 51 
RVSWI (gm/m 2per beat) 7.8 -- 4 92 
Exercise testing 
Heart rate--rest (beats/min) 95 + 17 79 
Heart rate--exercise (beats/min) 143 ± 24 79 
Systolic BP--rest (mm Hg) 114 _+ 20 77 
Systolic BP--exercise (mm Hg) 136 ± 30 79 
Diastolic BP--rest (mm Hg) 75 ± 12 76 
Diastolic BP--exercise (mm Hg) 83 _+ 15 77 
RPP--rest (beats. mm Hg/min) 108 ± 25 76 
RPP---exercise (beats. mm Hg/min) 195 2 57 79 
METS--rest 1.1 _+ 0.3 75 
METS---exercise 4.5 ± 1.6 79 
VO2--rest 343 ± 132 76 
VO2--exercise 1358 _+ 537 79 
Surgical factors 
Cardiopulmonary b pass used 22 126 
Concomitant procedure done 22 127 
IABP pump used 28 127 
Left ventricular coverage (%) 90 ± 2 85 
Right ventricular coverage (%) 70 ± 3 85 
Patch required to complete wrap 50 104 
n, Number of patients for whom the variable is available; SD, standard 
deviation; NYHA, New York Heart Association; CXR, chest x-ray film; 
EDVI, end-diastolic volume index; LVEDP, left ventricular end-diastolic 
pressure; LVEF, left ventricular ejection fraction; LVSWI, left ventricular 
stroke work index; PAP, pulmonary artery pressure; PCWP, pulmonary 
capillary wedge pressure; PVC, premature ventricular contraction; PVR, 
pulmonary vascular esistance; RVEF, right ventricular ejection fraction; 
RVSWI, right ventricular stroke work index; BP, blood pressure; RPP, rate 
pressure product; METS, metabolic equivalents; VOz maximum oxygen 
consumption; IABP, intraaortic balloon pump. 
relevance of these small but statistically significant 
objective changes is seen in dramatic improvements 
in NYHA class (Fig. 2) at both 6 and 12 months. 
Mean NYHA class for the group improved from 
3.2 +_ 0.05 to 1.6 + 0.6 (p < 0.0001) at 6 months and 
remained stable through 12 months as well. 
A Kaplan-Meier survival curve for all patients is 
shown in Fig. 3. Three patients were lost to follow- 
up. Cumulative patient follow-up totaled 204 pa- 
tient-years with an average of 1.7 _+ 0.1 years per 
patient (including procedural deaths). This Kaplan- 
Meier analysis portrays urvivals of 73% _+ 4%, 57% 
_+ 5%, 49% _+ 6%, 44% _+ 6%, and 40% _+ 7% at 
postprocedure years 1 through 5, respectively. 
Causes of death included ventricular failure (n = 
26), sudden death (n = 23), pulmonary embolus 
(n = 2), stroke (n = 1), and sepsis (n = 1). There 
was a significant difference in the causes of proce- 
dural versus long-term mortality. Procedural mor- 
tality was mostly due to ventricular pump failure 
(15/18 = 79%). Long-term mortality was mainly 
(48%) due to arrhythmias, with progressive CHF 
causing only 42% (13/28) of the late deaths (p = 
0.01 vs procedural death caused by pump failure). 
Preoperative demographic (n = 5), cardiac cath- 
eterization (n = 14), metabolic exercise testing (n = 
18), and surgical (n = 6) variables were first univa- 
riately compared (Table III). Univariately signifi- 
cant variables were then tested against overall sur- 
vival in a series of multivariable Cox regression 
analyses to determine which factors play a simulta- 
neous role in predicting the proportional hazard for 
long-term survival. This series of tests began with 
ma W variables and few patients. The least signifi- 
cant variables at the end of each run were progres- 
sively excluded to gain a larger sample of patients 
with complete data sets available for inclusion in the 
model. Once a model was finalized using only 
demographic, ardiac, and surgical variables (Cox 
model 1, Table III), cardiopulmonary metabolic 
exercise testing variables were then entered into the 
equation. This method significantly dropped the 
overall sample size (Cox model 2, Table III) but 
produced a distinct, but equally valid, model incor- 
porating preoperative oxygen consumption mea- 
surements in the equation. 
Cox regression model 1 included 101 of the 127 
cases (80%) and revealed that atrial fibrillation, 
elevated pulmonary capillary wedge pressure, 
NYHA class IV, and intraoperative r quirement for 
IABP counterpulsation were all independent pre- 
dictors of poor long-term survival. 
Inclusion of the cardiopulmonary metabolic test- 
ing results, in addition to the variables analyzed in 
Cox regression model 1, decreased the valid sample 
size for the second model to 76 patients (60%). In 
this model (Table III, Cox model 2), peak metabolic 
equivalents (METS) with exercise proved to be a 
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Table II. Univariate analysis of 90-day procedural mortality 
Variable Survivors Deaths p Value 
Demographics 
Age (yr) 
Center 
A (%) 
B (%) 
c (%) 
Male sex (%) 
Ischemic ause (%) 
NYHA class IV (%) 
Cardiac parameters 
Atrial fibrillation (%) 
Cardiac index (L/min/m z) 
Cardiothoracic ratio (CXR) (%) 
End-diastolic diameter (ram) 
EDVI (ml/m 2) 
LVEDP (mm Hg) 
LVEF (%) 
LVSWI (gm/m 2 per beat) 
PAP mean (ram Hg) 
PCWP (ram Hg) 
PVCs per hour 
PVR (dynes) 
RVEF (%) 
RVSWI 
Exercise testing 
Heart rate--rest  (beats/rain) 
Heart rate--exercise (beats/rain) 
& Heart rate (%) 
Systolic BP--rest  (ram Hg) 
Systolic BP--exercise (ram Hg) 
z~Systolic BP (%) 
Diastolic BP~rest  (mm Hg) 
Diastolic BP--exercise (mm Hg) 
A Diastolic BP (%) 
RPP- - rest  (beats. mm Hg/min) 
RPP--exercise (beats. mm Hg/min) 
A RPP (%) 
METS--rest  
METS--exercise 
METS (%) 
VO2--rest 
VO2--exercise 
a VO~ (%) 
Surgical factors 
Cardiopulmonary bypass used (%) 
Concomitant procedure done (%) 
IABP used (%) 
Left ventricular coverage (%) 
Right ventricular coverage (%) 
Patch required to complete wrap (%) 
50 ± 1 51 ± 4 0.805 
71 29 
94 6 0.059 
78 22 
82 85 0.730 
44 65 0.091 
24 45 0.094 
40 28 0.968 
2.3 ± 0.06 2.5 ± 0.2 0.408 
56 ± 0.6 60 -+ 2 0.068 
72 ± 1 74 -+ 5 0.361 
134 + 18 205 -+ 28 0.083 
22 ± 1 25 ± 4 0.342 
20 ± 1 20 ± 3 0.851 
24 ± 1 22 -+ 4 0.755 
31 ± 1 33 ± 3 0.485 
21 -+ 1 23 ± 8 0.400 
46 ± 17 19 -+ 18 0.578 
228 ± 19 214 ± 53 0.789 
27 -+ 1 17 ± 2 0.015 
7.5 ± 0.4 9.4 ± 1 0.142 
95 ± 2 105 m 4 0.055 
144 ± 2 154 2 9 0.199 
55 ± 3 48 ± 9 0.457 
115 ± 2 102 ± 5 0.028 
139 ± 3 110 ± 5 0.001 
20 2 2 8 + 4 0.048 
76 ± 1 66 ± 3 0.006 
85 ± 2 70 ± 3 0.003 
11 + 2 6 ± 4 0.258 
109 ± 3 107 ± 7 0.836 
202 ± 7 167 ± 9 0.053 
89 + 7 59 ± 9 0.100 
1.1 ± 0.04 1 ± 0.07 0.544 
4.4 ± 0.2 3.7 + 0.5 0.113 
328 ± 23 274 ± 6 0.378 
355 ± 17 286 ~ 24 0.119 
1409 ± 62 1039 ± 193 0.038 
327 ± 23 265 ± 53 0.325 
91 
69 
18 40 0.097 
80 70 0.354 
22 63 0.007 
2 90 ± 7 0.910 
3 75 ± 8 0.524 
47 60 0.378 
The number of patients (n) with valid data available for analysis is the same as that shown in table 1 for each variable. Comparison among the three centers 
was performed by a X = analysis (test statistic value = 5.67, with 2 degrees of freedom). NYHA, New York Heart Association; CXR, chest x-ray film; EDVI, 
end-diastolic volume index; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; LVSWI, left ventricular stroke work index; 
PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVC, premature ventricular contraction; PVR, pulmonary vascular resistance; 
RVEF, right ventricular ejection fraction; RVSWI, right ventricular stroke work index; BP, blood pressure; RPP, rate pressure product; METS, metabolic 
equivalents; VO~ maximum oxygen consumption; IABP, intraaortic balloon pump. 
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Fig. 1. Histogram comparing preoperative and 6 and 12 
month postoperative l ft ventricular ejection fractions 
(LVEF). Hatched bars represent one standard error of 
measurement. NS, Not significant. 
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Fig. 2. Stacked histograms of mean NYHA functional 
class before the operation and 6 and 12 months after the 
operation. 
strong surrogate for both pulmonary capillary wedge 
pressure and NYHA class, effectively eliminating 
these variables from the model. In this second 
model only peak METS, atrial fibrillation, and re- 
quirement for an IABP were significant predictors 
of a poor long-term outcome. 
Using the larger Cox regression model 1 (without 
exercise testing parameters), we generated a com- 
posite risk score for each patient in the series and 
plotted it against hat specific patient's actual sur- 
vival to date. This method of internal validation is 
presented as a scatter diagram in Fig. 4. 
Discussion 
As one can see from the scatter diagram (Fig. 
4), patients with high risk scores (above the 
composite risk = 0 line) tend to die early, with 
very few of these patients remaining alive beyond 
8°I 
• I 
4o 
2 
(13) (8) (1) 
I 
0 1 2 3 4 5 6 7 8 9 
Years Post-Procedure 
Fig. 3. Kaplan-Meier survival curve for 127 patients who 
underwent cardiomyoplasty between 1985 and 1994. 
Numbers above the curve represent the number of pa- 
tients surviving to that point in time. 
2 years. Patients with high composite risk scores 
tend to be grouped in the upper left-hand corner 
of the diagram, indicating a shorter overall sur- 
vival. On the contrary, patients with composite 
risks less than 0 have a much lower likelihood of 
death at any time after the cardiomyoplasty pro- 
cedure. Thus a much higher percentage of pa- 
tients represented in the bottom half of the scatter 
diagram continue to survive long term. 
This "composite risk score" generated from the 
Cox regression model enables one to estimate, for 
any patient in this series, the relative probability of 
a favorable long-term outcome. This is done by 
calculating the hazard multiplier for each patient, 
which is the exponentiated composite risk score. For 
example, when the composite risk score is 0, the 
hazard multiplier is 1. That is, the patient's hazard 
of dying is equal to that of the baseline hazard for 
the group. A negative composite score produces a 
hazard lower than the baseline hazard, whereas a 
positive score produces a hazard higher than the 
baseline hazard. 
One must be careful not to extrapolate his specific 
Cox regression model to other groups of patients. This 
model was created on a specific set of patients and only 
internally validated. As such, it is not the predictive 
model for all centers in which cardiomyoplasty is 
performed. Because we did not have the luxury of 
extremely large sample sizes, only internal validation 
of the model could be performed. A more stringent 
test of this model would be to plot the composite risks 
of a large group of patients having cardiomyoplasty at 
other centers against heir actual survival. External 
validation is the next logical step in determining a 
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Table II I .  Multivariable Cox regression analyses 
Model 1 (n = 101) Model 2 (n = 76) 
Variable Univariate p value p Value Risk ratio p Value Risk ratio 
Demographics 
Age (yr) 0.3 
Center 0.5 
Male sex 0.4 
Ischemic ause 0.5 
NYHA class 0.001 0.05 2.04 (1.02, 4.08) 
Cardiac parameters 
Atrial fibrillation 0.02 0.006 2.9 (1.4, 6.2) 0.004 5.0 (1.7, 14.9) 
Cardiac index 0.2 
Cardiothoracic ratio 0.05 
LVEDD 0.14 
EDVI 0.04 
LVEDP 0.2 
LVEF 0.4 
LVSWI 0.4 
PAP mean 0.02 
PCWP 0.01 0.01 1.05 (1.01, 1.09) 
PVCs per hour 0.8 
PVR 0.02 
RVEF 0.3 
RVSWI 0.2 
Exercise testing 
Heart rate--rest 0.2 
Heart rate--exercise 0.1 
2x Heart rate 0.1 
Systolic BP--rest 0.07 
Systolic BP--exercise 0.02 
2x Systolic BP 0.4 
Diastolic BP--rest 0.1 
Diastolic BP--exercise 0.2 
A Diastolic BP 1.0 
RPP--rest  0.5 
RPP--exercise 0.03 
A RPP 0.1 
METS--rest 0.8 
METS--exercise 0.009 0.001 0.53 (-37,  0.78) 
A METS 0.03 
VO2--rest 0.4 
VO2--exercise 0.03 
A VO2 0.05 * 
Surgical factors 
Cardiopulmonary b pass 
Concomitant procedure 0.9 
IABP 0.008 0.005 3.8 (1.5, 9.6) 0.012 4.7 (1.4, 15.5) 
Left ventricular coverage 0.7 
Right ventricular coverage 0.3 
Patch to complete wrap 0.8 
Date of operation 0.7 
Risk ratios are listed with 95% confidence intervals in parentheses. NYHA, New York Heart Association; LVEDD, left ventricular end-diastolic diameter; 
EDVI, end-diastolic volume index; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; LVSWI, left ventricular stroke work 
index; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVC, premature ventricular contraction; PVR, pulmonary vascular 
resistance; RVEF, right ventricular ejection fraction; RVSWI, right ventricular stroke work index; BP, blood pressure; RPP, rate pressure product; METS, 
metabolic equivalents; VO~ maximum oxygen consumption; IABP, Intraaortic balloon pump. 
*VO2 is a surrogate covariate of METS (see Discussion). 
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Fig. 4. Relationship of composite risk score generated from the Cox regression model (y-ax&) to actual 
survival after cardiomyoplasty (x-axis). 
universal risk stratification model of predictive survival 
for cardiomyoplasty. 
This type of population risk stratification for 
overall ong-term survival should be used to stratify 
the comparison of a group of patients having car- 
diomyoplasty with a control group of patients with 
CHF who are being medically treated. The risk 
stratification method of control obviates the need 
for specific matched controls between the groups. 
All variables found to be independent predictors of 
survival in this Cox regression have been previously 
shown to influence the natural history of medically 
treated patients with CHF as well.13 -15 
Atrial fibrillation has been shown to be an inde- 
pendent risk factor for early death in patients with 
CHF.  ]3 Patients with CHF and atrial fibrillation 
have been found to have significantly lower actuarial 
survival and sudden death-free survival than similar 
patients with sinus rhythm. Atrial fibrillation as a 
risk factor might also apply to patients with second- 
degree heart block or junctional rhythm, because 
loss of the atrial kick results in a 25% decrease in 
stroke volume. Other possible mechanisms for de- 
creased survival caused by atrial fibrillation include 
an increased potential for thromboembolic events 
and an increased risk of ventricular tachyarrhyth- 
mias. 14 There also exists the possibility that atrial 
fibrillation may be a marker for an immeasurable 
component of the severity and chronicity of left 
ventricular dysfunction. 
Elevated pulmonary capillary wedge pressure has 
been shown to increase the risk of death in patients 
with CHF) 3' 15 Likewise, increased pulmonary ar- 
tery diastolic pressure has also been shown to have 
a negative prognostic significance in medically 
treated patients with CHF. 15 These two pulmonary 
pressure measurements tend to be highly dependent 
covariates. In this series elevation of pulmonary 
capillary wedge pressure proved to be a statistically 
stronger multivariate predictor of death, thereby 
eliminating pulmonary artery diastolic pressure 
from the final regression. 
Peak oxygen consumption and its mathematical 
correlate, peak METS, are known to be codepen- 
dent predictors of the risk of hem•dynamic deteri- 
oration in patients with CHF. 15 In this study, peak 
METS proved to be a statistically stronger variable. 
However, when peak METS was removed from the 
model, peak oxygen consumption (or alternatively, 
peak oxygen consumption per kilogram) immedi- 
ately took its place in the equation with an equally 
strong predictive risk (p = 0.001, /3 coefficient = 
0.9983). 
The requirement for IABP connterpulsation at
the time of the operation greatly increases the risk 
of early death, as seen in Fig. 5, A. The effect of 
IABP use on long-term survival is not as dramatic as 
its effect on procedural mortality. When IABP use at 
the time of the operation was excluded from both 
multivariate models, no other variables came into 
the equation. Therefore IABP use did not mask any 
other variables available for analysis that might play 
an important role in long-term outcome. Although 
the requirement for an IABP at the time of cardio- 
myoplasty may be a risk that is difficult to avoid, it 
may also be a surrogate variable that signifies a 
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Fig. 5. Effect of four independent predictors of poor long-term survival that were identified by the Cox 
proportional hazards model. In each of these figures the survival of patients with and without he respective 
risk factor is compared. These predictors include IABP use (A), oxygen consumption (V02) (B), atrial 
fibrillation (AFIB) (C), and pulmonary capillary wedge pressure (D). Note IABP and oxygen consumption 
effect on procedural deaths and effect of atrial fibrillation and pulmonary capillary wedge pressure on late 
deaths. The p values are based on the log-rank test statistic. NSR, Normal sinus rhythm. 
degree of myocardial damage and fibrosis beyond 
that which is indicated by traditional measures of 
left ventricular dysfunction. 
The individual effect of each of these four inde- 
pendent predictors on long-term survival is illus- 
trated in Fig. 5, A to D. In each part of this figure, 
the Kaplan-Meier survival of patients with and 
without the respective risk factor is compared. As 
can be seen, all four parts show highly significant 
differences for each independent predictor of risk. 
For continuous variables, such as pulmonary capil- 
lary wedge pressure and maximum oxygen consump- 
tion, curves were generated for each patient group 
according to commonly accepted risk cutoffs. Close 
examination of Fig. 5, A and B reveal that intraop- 
erative use of an IABP and a blunted hemodynamic 
response to preoperative xercise testing, as evi- 
denced by a low peak oxygen consumption, are 
variables that greatly influence procedural mortality 
as opposed to long-term mortality. Conversely, 
atrial fibrillation and elevated pulmonary capillary 
wedge pressure have virtually no effect on proce- 
dural mortality, whereas they dramatically alter the 
late survival of patients who have undergone cardio- 
myoplasty. As such, the presence of atrial fibrillation 
or high pulmonary capillary wedge pressures should 
not influence surgeons to exclude patients from 
undergoing cardiomyoplasty, because they do not 
alter the immediate procedural risk. However, peak 
oxygen consumption and intraoperative use of an 
IABP do have procedural prognostic significance. 
Inasmuch as cardiomyoplasty is currently being 
performed in nearly all areas of the globe, the 
importance in predicting survival, with and without 
intricate metabolic exercise testing, becomes obvi- 
ous. Control patients who may not have undergone 
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this expensive screening procedure may be easily 
compared with cardiomyoplasty patients who have 
undergone metabolic testing. Nonetheless, both Cox 
proportional hazard models are valid and should be 
applied to the appropriate groups. A blunted hemo- 
dynamic response to exercise testing may be a more 
cost-effective method of predicting a patient's pro- 
cedural risk in centers where no complex metabolic 
testing equipment exists. Nonetheless, cardiopulmo- 
nary exercise testing remains the single best method 
to evaluate patients for risk of procedural mortality. 
A multicenter group of 117 patients compiled by 
the Phase II Dynamic Cardiomyoplasty Study 
Group 7 showed that although several factors were 
univariately associated with procedure-related 
death, only peak oxygen consumption and left ven- 
tricular ejection fraction provided independent 
prognostic information, according to a logistic re- 
gression analysis. In the present study, with a valid 
sample size of only one third of the total patient 
population, no consistent logistic regression analysis 
could be produced. Depending on the specific sam- 
ple, each of the following variables was found to be 
a single independent predictor of risk by means of 
multivariable regression analysis: right ventricular 
ejection fraction, IABP use, peak METS, or peak 
oxygen consumption. 
Preoperative NYHA class, in and of itself, should 
not be used as an exclusionary criterion in screening 
patients for cardiomyoplasty when metabolic exer- 
cising test data are available. Oxygen utilization 
measurements, obtained through exercise testing, 
are far superior to subjective NYHA classification i
assessing a patient's procedural risk. Cardiopulmo- 
nary metabolic testing is extremely objective and the 
results are reported as a finely graded continuous 
score indexed to the patient's body size. These 
highly sensitive measurements carry much more 
precision than a subjective NYHA class in predict- 
ing procedural outcome. 
The traditional definition of 30-day operative 
mortality has been modified in this analysis to an 
expanded 90-day procedural mortality. The ratio- 
nale for this expanded time frame is both theoretical 
and real. The cardiomyoplasty procedure involves 
both an operation at a specific point in time and a 
prolonged muscle conditioning period that eventu- 
ally allows that patient o achieve a clinical benefit 
from the operation. Unlike other surgical proce- 
dures, the patient does not immediately benefit from 
cardiomyoplasty within the first 30 days after oper- 
ation. Skeletal muscle conversion to type I fibers 
capable of fatigue-resistant cardiac augmentation 
takes a full 12 weeks. 9Thus patients who die within 
90 days of the procedure cannot clinically benefit 
from the procedure. In addition, mathematical nal- 
ysis of the Kaplan-Meier survival curve (see Fig. 3) 
reveals a steep procedural mortality that extends to 
3 months. This is then followed by a prolonged 
survival curve in which the death rate is markedly 
diminished. A linear fit to these two portions of the 
survival curve intersects at 90 days. For these rea- 
sons we thought hat the 90-day procedural mortal- 
ity end point for cardiomyoplasty was a more valid 
clinical and scientific oncept. 
Summary 
This compiled multicenter study of 127 patients 
undergoing cardiomyoplasty reveals an acceptable 
long-term mortality that is altered by naturally oc- 
curring risks in patients with CHF. A 90-day proce- 
dural mortality is specifically appropriate to the 
cardiomyoplasty procedure in both the theoretical 
and the scientific sense. This procedural mortality is 
seen to be affected by low preoperative oxygen 
consumption on exercise testing and by the intraop- 
erative requirement for IABP counterpulsation. Pa- 
tients in NYHA class IV should not be excluded 
during the screening process when more objective 
and detailed peak oxygen consumption data are 
available. Likewise, atrial fibrillation and high pul- 
monary capillary wedge pressures hould not be 
used to specifically exclude patients from the proce- 
dure, because these variables have an impact on late 
survival but do not seem to affect procedural mor- 
tality. 
We conclude that the results of dynamic ardio- 
myoplasty for symptomatic CHF may be enhanced 
by intelligent, risk-sensitive patient selection. In 
addition, future outcomes comparison of patients 
with CHF treated either medically or by cardiomy- 
oplasty should be performed on the basis of Cox risk 
stratification. 
We greatly appreciate the kind and invaluable services 
of Andrew J Bennett, Natasha C Pfeifer, Cindy L Fessler, 
and Jennifer L. Bolger for assistance in preparation of the 
manuscript and figures. 
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Discussion 
Dr. Richard J. Hurvitz (Los Angeles, Calif.). The con- 
cept of transforming a readily available skeletal muscle 
into functioning cardiac muscle and then positioning this 
muscle so as to augment failing heart muscle is truly an 
exciting concept. However, why then after more than 10 
years since the concept first materialized is the procedure 
still controversial, particularly here in the United States? 
The coronary bypass graft as well as valve replacement 
both rapidly gained acceptance and proliferated in expo- 
nential fashion. Heart transplantation initially went 
through a skeptical phase but is now firmly established as 
an accepted treatment modality. There are estimated to 
be more than 2 million patients here in the United States 
with chronic CHF and an estimated 400,000 new cases 
each year. I believe the controversy over cardiomyoplasty 
has lingered for this relatively long period of time because 
the data to validate this procedure have not been convinc- 
ing and the mechanism of action has not been well 
defined. I want to congratulate Dr. Furnary on his attempt 
to retrospectively retrieve information from three major 
centers performing cardiomyoplasty that ideally will shed 
some additional light on cardiomyoplasty. We can agree 
with Dr. Furnary's conclusion that cardiomyoplasty may 
be an effective form of therapy for patients with symptom- 
atic CHF. However, additional data will be necessary to 
validate this. The Medtronic phase III study, which is a 
randomized trial comparing standard medical therapy for 
CHF versus standard medical therapy plus cardiomyo- 
plasty, should help address this issue. This study recently 
got underway. Those of us who have followed cardiomy- 
oplasty over the years are awaiting information that will 
either vindicate this procedure or inspire development of
a modified procedure that will use the general concept of 
using the transformed skeletal muscle to assist he failing 
heart. Ideally, with regard to cardiomyoplasty, it will not 
be the case that when all is said and done, more will be 
said than done. 
I have several questions for Dr. Furnary. First, what is 
your opinion of the mechanism of action of cardiomyo- 
plasty? 
Dr. Furnary. We believe there are three possible mech- 
anisms for cardiomyoplasty. First is its effect on systolic 
function and augmentation thereof. At the phase II results 
from cardiomyoplasty, which were presented at the Amer- 
ican Heart Association meeting, there was a significant 
increase in stroke volume and stroke work index. These 
were statistically and clinically significant. 
The second theory is that dynamic cardiomyoplasty 
inhibits the progressive dilation of the ventricle during 
exercise, specifically submaximal exercise. 
Finally there is the theory that electrical stimulation of 
a neuromuscular complex may alter the neurohumoral 
baseline status of the patient, such that there are in- 
creased levels of circulating catecholamines which may 
indirectly affect patient well-being and cardiac function. 
Dr. Iturvitz. Which do you think is the dominant 
factor? 
Dr. Furnary. The only scientifically proven dominant 
factor from the phase II study is systolic augmentation. 
Dr. D. Craig Miller (Stanford, Calif.). What about 
diastole? 
Dr. Furnary. There have been experimental results 
showing improvement in diastolic function; however, the 
application of the clinical mechanisms to evaluate dia- 
stolic function such as the use of conductance catheters 
has not been applied to this group of patients. It has only 
been applied in the laboratory, but there are very good 
laboratory results suggesting that there may be some 
improvement in diastolic function. 
Moderator. I rather disagree with you there. There was 
a study from Belgium just a couple months ago showing 
that diastolic function was in fact the most predominant. 
Dr. Furnary. Thank you. I missed that paper. 
Dr. Hurvitz. Cardiomyoplasty has been labeled as an 
alternative for cardiac transplantation. In view of your 
conclusion, I believe th~it you state that patients in NYHA 
class IV should not be excluded from the procedure. Do 
you believe this procedure is an alternative for heart 
transplantation? 
Dr. Furnary. I do not and I have not classified the 
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procedure as an alternative to heart transplantation r a 
replacement thereof. I personally have positioned this 
procedure as an adjuvant o medical therapy for those 
patients who do not respond to medical therapy. For 
patients who are receiving maximum medical therapy, 
who are in class III or in early class IV CHF, and have not 
responded, this is an adjuvant procedure for medical 
therapy. We do not take patients off of their medical 
therapy, and certainly this is not meant o replace cardiac 
transplantation. I  its present state I do not think it will. 
Twelve patients world wide have gone on to transplanta- 
tion from cardiomyoplasty. 
In terms of patients with NYHA class IV disease, I 
believe that exercise testing parameters for oxygen con- 
sumption are much more precise and are much more 
objective than NYHA class in assessing a patient's risk. 
However, not all centers around the world may have these 
expensive pieces of equipment available to them. They 
could fall back on the measurement of pulmonary pres- 
sures and NYHA subjective class to assess preoperative 
risk. 
Dr. tInrvitz. How do you think the stance adopted by 
Medicare and some private insurance agencies on reim- 
bursing for experimental devices will affect he progress of 
the project here in the United States? 
Dr. Furnary. That is a complex question. Actually it ties 
in with what you said originally, because this is a contro- 
versial procedure. Part of the controversy relates to the 
fact that we still do not know whether this modifies or 
improves patient survival. We have seen subjective im- 
provements in CHF, but again that is a clinical controver- 
sial area. 
There is also the controversial area of payment for 
experimental procedures. This is the first surgical proce- 
dure that is fully regulated by the Food and Drug Admin- 
istration, and they have told us how it has to be done. 
None of the modifications that have come to bear over the 
past 5 or 6 years in the laboratory may be used or 
incorporated into the procedure. Also, in terms of the 
Food and Drug Administration and the Health Care 
Financing Administration, there remains the paradox. 
Although the FDA wants us to do this study and we want 
to do this study and find out whether it really does affect 
long-term mortality, Medicare will not pay for the proce- 
dure because it is experimental. It is not necessarily paying 
for the procedure but the hospital stay related to the 
procedure. The hospitals have to write off the entire cost 
of this procedure, and the only centers are actively 
performing this procedure in this country are centers that 
have large clinical endowments for clinical experimental 
surgery. Some of the centers have had large fund raisers 
specifically for this purpose, but insurance companies 
follow suit with Medicare. Until the paradox is resolved at 
the governmental level, the development of this proce- 
dure will stagnate in the United States. At the same time, 
the procedure is proliferating throughout Europe and 
Asia and South America. 
Dr. Miller. Were these cardiomyoplasties all left poste- 
rior wraps? Were there any right anterior wraps? 
Dr. Furnary. There were no right anterior wraps. There 
was one right posterior wrap for a patient with right 
ventricular failure, but otherwise this series comprised 
exclusively left ventricular wraps. 
Dr. Noel H. Fishman (Santa Cruz, Calif.). Your re- 
peated emphasis on the "statistically significant" but 
rather small (only 2%) increase in left ventricular ejection 
fraction after cardiomyoplasty promotes the inference 
that you consider it an "important" determinant in the 
dramatic improvement in the NYHA classification of 
these patients. I find this hard to believe. 
Clinical improvement is, of course, a subjective phe- 
nomenon and could have been related to other factors 
such as improved rug treatment regimens. Do you have 
any other physiologic data to support your hypothesis? 
Dr. Fnrnary. What your question really comes down to 
is, is it clinically significant, hat is, does it make a clinical 
difference? A 2% difference in ejection fraction in and of 
itself would not seem to make a difference. However, 
remember that an absolute increase of 2% in a patient 
with a 20% ejection fraction amounts to a 10% relative 
increase in ejection fraction. That may be clinically signif- 
icant for someone in class III CHF. The only clinical 
evidence we have is the dramatic improvement in the 
patient's NYHA class, which becomes very significant. We 
are attempting to identify measurements in between those 
two, such as the highly precise oxygen consumption mea- 
surements that will be used in phase III to determine 
whether that small percentage increase in ejection frac- 
tion has a clinically significant impact on oxygen consump- 
tion. This I think would better answer your question of 
does that 2% turn out to be clinically significant, because 
left ventricular ejection fraction is not the only parameter 
of heart function that is important. It is one of them, but 
it is certainly not the only one. Left ventricular stroke 
work is important. Diastolic function is important. Oxygen 
consumption is important as well. 
